Is CCL18 a potential biomarker of type-2 asthma endotypes? - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Journal of Asthma Année : 2022

Is CCL18 a potential biomarker of type-2 asthma endotypes?

Jonathan Giovannelli

Résumé

Objective: This exploratory cross-sectional study aimed to evaluate the associations between the chemokine ligand 18 (CCL18) blood level and phenotypic characteristics of asthma.Methods: We evaluated in a sample of 173 asthmatic adult patients from the Cohort of Bronchial obstruction and Asthma (63.4% women; median age 50 +/- interquartile range 27.5 years; median level of CCL18 was 44.1 +/- interquartile range 27.5 ng/mL) the association between CCL18 blood level and allergic features of asthma using a multivariate analysis. Results: We found an association between the log-transformed value of blood CCL18 and age (+0.7% [0.1; 1.3] per 1-year increase, p = 0.033), gender (-25.1% [-42; -3.2] in women, p = 0.029), and nasal polyposis (+38.1% [11.6; 70.9], p = 0.004). No association was observed between CCL18 level and the other main phenotypic characteristics of asthma. Conclusions: Our exploratory study suggests that CCL18 is not an effective biomarker of allergic asthma endotype but may rather be a biomarker of tissue eosinophilia as supported by its association with nasal polyposis.
Fichier principal
Vignette du fichier
2020 Fouquet et al., is CCL18 a potential.pdf (15.69 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03046944 , version 1 (29-07-2021)

Identifiants

Citer

Helen Fouquet, Jonathan Giovannelli, Patricia de Nadaï, Joanne Balsamelli, Patrick Berger, et al.. Is CCL18 a potential biomarker of type-2 asthma endotypes?. Journal of Asthma, In press, pp.1-9. ⟨10.1080/02770903.2020.1861623⟩. ⟨hal-03046944⟩
123 Consultations
94 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More